Core Viewpoint - Baixinan-B (02185) experienced a significant increase of over 52% in stock price, reaching HKD 9.22 with a trading volume of HKD 98.296 million, following the announcement of its Iberis RDN system receiving a 5-year healthcare qualification in France [1] Group 1: Product Development and Market Expansion - The Iberis RDN system has been granted a 5-year healthcare qualification by French authorities, with the potential for renewal, enhancing the clinical application support system in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Group 2: Clinical Success and Market Potential - In February, Baixinan's subsidiary, Shanghai Antong Medical, completed the first commercial procedure of the Iberis RDN system in Germany [1] - According to CITIC Securities, the RDN procedure shows significant and long-term effective blood pressure reduction, with a simple operation and low complication rates, indicating a broad long-term market potential [1] - The company's RDN products are advancing commercialization simultaneously in domestic and international markets, with a focus on the results of the first year of commercialization in 2025 [1]

Core Viewpoint - 百心安-B's stock surged over 52% following the announcement of its Iberis RDN system receiving a five-year healthcare qualification in France, indicating strong market potential and positive clinical developments [1] Company Developments - 百心安's Iberis RDN system has been granted a five-year healthcare qualification by French authorities, with the possibility of renewal, enhancing its clinical application support in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Market Performance - As of the latest report, 百心安-B's stock price reached 9.22 HKD, with a trading volume of 98.2961 million HKD, reflecting strong investor interest [1] - 中信建投 highlighted the significant and long-term effectiveness of RDN in lowering blood pressure, along with its simple procedure and low complication rates, suggesting a broad long-term market potential [1] Commercialization Progress - 百心安's Iberis RDN system completed its first commercial procedure in Germany in February this year, marking a significant milestone in its commercialization efforts [1] - The company is advancing the commercialization of its RDN products both domestically and internationally, with a focus on the results of its first year of commercialization in 2025 [1]

Core Viewpoint - The article highlights the significant advancements in hypertension treatment with the successful clinical application of the Iberis RDN system at Hospital Universitario de Torrejón de Ardoz in Madrid, emphasizing its academic value and clinical potential in treating uncontrolled hypertension [2][5]. Group 1: Technological Innovation - The Iberis RDN system represents a breakthrough in renal denervation (RDN) procedures by utilizing the radial artery for access, which reduces trauma and recovery time compared to traditional femoral artery approaches [5]. - The system employs a unique design with a circular four-electrode ablation mechanism and a <4Fr catheter, allowing for precise adaptation to the complex anatomy of renal arteries, enhancing treatment efficacy [10]. - Integrated features such as wall contact testing, precise temperature control, and safety cut-off functions improve the accuracy and stability of the procedure [10]. Group 2: Clinical Outcomes - A case study reported a 43-year-old patient with hereditary resistant hypertension who experienced significant symptom improvement and reduced medication usage following the RDN procedure, showcasing the system's effectiveness [7]. - The rapid recovery and positive feedback from patients have been noted as redefining the recovery experience for hypertension surgeries [7]. Group 3: Future Prospects - The Iberis RDN technology is expected to benefit Spanish hypertension patients, particularly those with poor drug control or intolerance to multiple medications, providing new treatment pathways [8]. - The recognition of the technology's safety and efficacy by Spanish media supports its potential for broader application, including improvements in arrhythmia management [8]. - Ongoing multi-center clinical practices and evidence development are anticipated to further validate the technology's potential in diverse applications for hypertension treatment [8].